Glenmark Pharmaceuticals Sees Surge in Call Option Activity Amid Bullish Momentum

Robust Call Option Activity Highlights Investor Optimism

On 7 January 2026, Glenmark Pharmaceuticals witnessed an impressive surge in call option trading, with 9,730 contracts exchanged at the 2,100 strike price for the expiry dated 27 January 2026. This activity generated a turnover of approximately ₹2,330.46 lakhs, reflecting heightened speculative interest. The open interest stands at 1,229 contracts, indicating sustained positions held by traders anticipating further upside.

The underlying stock price closed at ₹2,133.40, comfortably above the strike price, reinforcing the bullish positioning. The call option volume and turnover are among the highest recorded for Glenmark in recent months, underscoring a growing conviction in the stock’s near-term appreciation.

Price Performance and Technical Strength

Glenmark outperformed its Pharmaceuticals & Biotechnology sector peers by 2.16% on the day, registering a 2.77% gain compared to the sector’s 0.98% rise and the Sensex’s marginal decline of 0.15%. The stock has been on a positive trajectory for two consecutive sessions, delivering a cumulative return of 5.04% over this period.

Intraday, Glenmark touched a high of ₹2,147.50, marking a 3.51% increase from the previous close. The stock is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling strong technical momentum and a favourable trend for buyers.

However, it is noteworthy that delivery volume on 6 January fell sharply by 81.37% to 95,060 shares compared to the five-day average, suggesting a temporary dip in investor participation despite the price gains. Liquidity remains adequate, with the stock capable of handling trade sizes up to ₹1.34 crore based on 2% of the five-day average traded value.

Fundamental Upgrade Fuels Positive Sentiment

On 6 June 2025, Glenmark Pharmaceuticals was upgraded from a Hold to a Strong Buy rating, reflecting improved fundamentals and growth prospects. The company’s Mojo Score stands at an impressive 91.0, the highest in its sector, signalling robust financial health and operational efficiency. Despite a Market Cap Grade of 2, categorising it as a mid-cap stock with a market capitalisation of ₹59,530 crore, Glenmark’s valuation metrics and earnings outlook have strengthened considerably.

This upgrade has likely contributed to the increased call option activity, as investors position themselves to capitalise on anticipated price appreciation driven by strong earnings growth, pipeline developments, and favourable industry dynamics.

Expiry Patterns and Strike Price Analysis

The concentration of call option contracts at the ₹2,100 strike price for the 27 January 2026 expiry suggests that market participants expect the stock to maintain or exceed this level in the short term. Given the current underlying price of ₹2,133.40, this strike price is slightly in-the-money, offering an attractive risk-reward profile for option buyers.

Open interest data indicates that traders are not only initiating new positions but also holding onto existing ones, which may lead to increased volatility as the expiry date approaches. This pattern is typical in a bullish scenario where investors seek leveraged exposure to potential upside moves without committing to outright stock purchases.

Sector Context and Comparative Performance

Within the Pharmaceuticals & Biotechnology sector, Glenmark’s recent outperformance is notable. The sector has been relatively stable, with many stocks consolidating after recent gains. Glenmark’s ability to outperform by over 2% on the day highlights its relative strength and investor preference amid sector rotation.

Moreover, the stock’s consistent trading above all major moving averages contrasts with some peers that remain range-bound or face resistance at key technical levels. This technical advantage, combined with fundamental upgrades, positions Glenmark favourably for continued momentum.

Implications for Investors and Traders

The surge in call option volumes and turnover at a strike price close to the current market level suggests that investors are positioning for a near-term rally in Glenmark Pharmaceuticals. Traders may view this as an opportunity to leverage bullish momentum through options, which offer asymmetric payoffs compared to direct equity exposure.

However, the sharp decline in delivery volumes signals some caution among long-term holders, possibly reflecting profit-booking or selective participation. Investors should monitor upcoming earnings announcements, regulatory developments, and sector trends that could influence the stock’s trajectory.

Given the stock’s strong technical setup and fundamental upgrade, Glenmark remains a compelling candidate for those seeking exposure to the Pharmaceuticals & Biotechnology sector’s growth potential. The call option activity serves as a useful barometer of market sentiment and can guide tactical positioning ahead of the 27 January expiry.

Conclusion

Glenmark Pharmaceuticals Ltd. is currently at the forefront of call option trading activity, driven by a combination of robust price performance, a recent upgrade to Strong Buy, and positive sector dynamics. The concentration of call contracts at the ₹2,100 strike price for the upcoming expiry reflects widespread bullish expectations. While delivery volumes have dipped, the overall technical and fundamental picture supports continued investor interest.

Market participants should keep a close eye on option open interest trends and price action in the coming weeks to gauge the sustainability of this momentum. Glenmark’s blend of strong fundamentals, technical strength, and active derivatives market positioning makes it a stock to watch in the Pharmaceuticals & Biotechnology space.

Unlock special upgrade rates for a limited period. Start Saving Now →